| Quarterly Financials | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 681 | 916 | 852 | 895 | 935 | 1,216 | 1,132 | 1,109 | 1,168 | 931 | 1,110 | 1,000 | 824 | 1,246 | 1,427 | 1,583 | 1,580 | 1,453 | 1,466 | 1,443 |
| Expenses | 395 | 472 | 534 | 595 | 560 | 718 | 704 | 714 | 755 | 587 | 748 | 649 | 673 | 915 | 1,049 | 1,189 | 1,179 | 1,137 | 1,109 | 1,024 |
| EBITDA | 286 | 445 | 318 | 299 | 375 | 498 | 428 | 395 | 414 | 344 | 363 | 351 | 151 | 332 | 377 | 394 | 401 | 316 | 357 | 418 |
| Operating Profit % | 38 % | 47 % | 36 % | 31 % | 37 % | 38 % | 35 % | 33 % | 32 % | 32 % | 28 % | 31 % | 14 % | 24 % | 24 % | 23 % | 23 % | 19 % | 21 % | 26 % |
| Depreciation | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 28 | 31 | 35 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 |
| Profit Before Tax | 262 | 420 | 293 | 273 | 349 | 472 | 401 | 366 | 381 | 309 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 |
| Tax | 67 | 106 | 74 | 69 | 89 | 121 | 99 | 93 | 95 | 79 | 83 | 79 | 33 | 67 | 96 | 91 | 106 | 75 | 93 | 95 |
| Net Profit | 195 | 314 | 219 | 204 | 260 | 351 | 302 | 273 | 286 | 229 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 |
| EPS in ₹ | 12.57 | 20.24 | 14.12 | 12.83 | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 13.93 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 |
Gland Pharma
1,612.20
-42.50
(-2.57%)
There are 3 new updates from the company42 minutes ago
View
Market Cap
26,561.27 Cr
EPS
46.90
PE Ratio
38.72
Dividend Yield
1.21 %
Industry
Healthcare52 Week High
2,220.95
52 Week low
1,411.10
PB Ratio
3.10
Debt to Equity
0.02
Sector
Pharmaceuticals
Live Chart 
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
| 1,656.00 | 3,97,329.87 | 32.77 | 49,887.20 | 12.06 | 9,648 | 13.77 | 37.72 | |
| 5,550.85 | 1,47,357.63 | 70.79 | 8,184.00 | 0.89 | 1,600 | 64.53 | 39.06 | |
| 1,440.60 | 1,16,344.88 | 23.67 | 26,520.70 | 14.17 | 4,155 | 47.38 | 53.19 | |
| 3,066.20 | 1,03,774.14 | 55.81 | 10,785.70 | 11.59 | 1,656 | 13.54 | 48.49 | |
| 1,116.35 | 93,149.46 | 17.40 | 28,905.40 | 12.36 | 5,578 | 1.69 | 32.01 | |
| 2,210.00 | 91,177.28 | 45.68 | 10,615.60 | 19.57 | 1,942 | -16.38 | 36.72 | |
| 899.15 | 90,475.53 | 19.82 | 19,831.50 | 13.82 | 3,831 | 29.92 | 43.14 | |
| 1,974.10 | 90,057.96 | 31.98 | 20,141.50 | 19.94 | 1,936 | 38.82 | 48.40 | |
| 30,600.00 | 65,022.86 | 48.79 | 6,097.20 | 10.80 | 1,201 | 16.01 | 59.83 | |
| 1,090.00 | 63,307.38 | 18.00 | 29,559.20 | 17.55 | 3,169 | -10.04 | 42.91 |
Growth Rate
Revenue Growth
50.97 %
Net Income Growth
-1.09 %
Cash Flow Change
173.87 %
ROE
-9.79 %
ROCE
-5.23 %
EBITDA Margin (Avg.)
-21.30 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 |
| Fixed Assets | 968 | 954 | 1,502 | 1,571 | 3,947 |
| Current Assets | 2,846 | 5,124 | 5,852 | 6,901 | 5,645 |
| Capital Work in Progress | 189 | 338 | 191 | 177 | 238 |
| Investments | 0 | 0 | 155 | 0 | 0 |
| Other Assets | 2,930 | 5,204 | 5,986 | 7,030 | 6,477 |
| Total Liabilities | 4,086 | 6,496 | 7,834 | 8,778 | 10,661 |
| Current Liabilities | 359 | 513 | 582 | 729 | 1,398 |
| Non Current Liabilities | 81 | 80 | 94 | 90 | 539 |
| Total Equity | 3,646 | 5,903 | 7,158 | 7,959 | 8,724 |
| Reserve & Surplus | 3,631 | 5,887 | 7,141 | 7,942 | 8,707 |
| Share Capital | 16 | 16 | 16 | 17 | 17 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | -67 | 323 | -174 | 1,590 | -1,552 |
| Investing Activities | -761 | -1,520 | -999 | 1,211 | -1,749 |
| Operating Activities | 701 | 605 | 791 | 364 | 997 |
| Financing Activities | -7 | 1,239 | 35 | 15 | -799 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
| Promoter | 58.25 % | 58.14 % | 58.02 % | 58.00 % | 58.00 % | 57.87 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 57.86 % | 51.83 % | 51.83 % | 51.83 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.01 % | 0.01 % | 0.00 % | 4.91 % | 0.00 % | 3.59 % | 6.88 % | 4.47 % | 5.04 % |
| DIIs | 10.69 % | 11.57 % | 11.39 % | 11.21 % | 11.94 % | 16.71 % | 20.58 % | 23.13 % | 23.23 % | 23.38 % | 22.45 % | 23.14 % | 25.23 % | 32.83 % | 35.37 % | 34.80 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 3.30 % | 3.72 % | 3.77 % | 3.58 % | 3.69 % | 3.70 % | 3.77 % | 4.02 % | 4.26 % | 5.60 % | 4.52 % | 3.79 % | 3.28 % | 3.33 % | 3.28 % | 3.30 % |
| Others | 27.76 % | 26.58 % | 26.81 % | 27.21 % | 26.37 % | 21.71 % | 17.78 % | 14.98 % | 14.64 % | 13.16 % | 10.27 % | 15.22 % | 10.04 % | 5.12 % | 5.04 % | 5.04 % |
| No of Share Holders | 84,467 | 98,203 | 1,09,326 | 1,09,097 | 1,09,098 | 1,17,339 | 1,27,879 | 1,48,469 | 1,50,578 | 1,81,747 | 1,61,627 | 1,36,021 | 1,22,375 | 1,22,665 | 1,22,358 | 1,21,075 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.21 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of Directors
Approval Of Gland Pharma Employee Stock Option Scheme 2025 By Board Of Directors
Board Meeting Outcome for Outcome Of Board Meeting - 26Th February 2025
Board Meeting Outcome for Outcome Of Board Meeting - 26Th February 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Conclusion Of US FDA Inspection At CompanyS JNPC Facility Visakhapatnam
Conclusion Of US FDA Inspection At CompanyS JNPC Facility Visakhapatnam
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Integrated Filing (Financial)
Announcement under Regulation 30 (LODR)-Investor Presentation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Board Meeting Outcome for Outcome Of Board Meeting For The Quarter Ended December 31 2024
Unaudited Financial Results For The Quarter Ended December 31 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication
Update On US FDA Inspection At Pashamylaram Facility Hyderabad
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2024
Update On USFDA Inspection At Dundigal Facility
Announcement under Regulation 30 (LODR)-Change in Management
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Closure of Trading Window
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Shareholder Meeting / Postal Ballot-Scrutinizers Report
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Announcement under Regulation 30 (LODR)-Change in Management
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Newspaper Publication
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Announcement under Regulation 30 (LODR)-Newspaper Publication
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Company Filings to Exchanges
Technical Indicators
RSI(14)
Neutral 62.28
ATR(14)
Less Volatile 65.84
STOCH(9,6)
Neutral 68.83
STOCH RSI(14)
Overbought 98.76
MACD(12,26)
Bullish 22.56
ADX(14)
Strong Trend 33.49
UO(9)
Bearish 52.37
ROC(12)
Uptrend And Accelerating 12.46
WillR(14)
Overbought -7.48
About Gland Pharma
Gland Pharma Limited is an Indian generic injectables manufacturer specializing in sterile injectables, oncology, and ophthalmic products. Founded in 1978, the company operates primarily on a B2B model, selling products in over 60 countries. It has 8 manufacturing facilities in India, including 4 for finished formulations and 3 for APIs. The company has 284 ANDA filings in the US, with 234 approved. It expanded its business to include contract development, dossier preparation, and technology transfer. In 2023, Gland Pharma acquired Cenexi through its Singapore subsidiary, adding 7 new subsidiaries. The company offers various delivery systems and key molecules such as Heparin Sodium and Enoxaparin Sodium Injections.
Listing Date
20 Nov, 2020(4 Years,
19 days)
Website
Chairperson NameYiu Kwan Stanley Lau
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
